High-purity phospholipids
AssigneeVascular Biogenics Ltd.
InventorsGideon Halperin, Eti Kovalevski-Ishai
Life of this patent
Estimating the term…
Abstract
Novel synthetic routes, which are highly applicable for industrial preparation of therapeutically beneficial oxidized phospholipids are disclosed. Particularly, novel methods for efficiently preparing compounds having a glycerolic backbone and one or more oxidized moieties attached to the glycerolic backbone, which are devoid of column chromatography are disclosed. Further disclosed are novel methods of introducing phosphorus-containing moieties such as phosphate moieties to compounds having glycerolic backbone and intermediates formed thereby. Further disclosed is substantially pure 1-hexadecyl-2-(4′-carboxy)butyl-sn-glycero-3-phosphocholine (CI-201).
Claims20
1-hexadecyl-2-(4′-carboxy)butyl-sn-glycero-3-phosphocholine (CI-201) being substantially pure.
1-hexadecyl-2-(4′-carboxy)butyl-sn-glycerol-3-phosphocholine (CI-201) being substantially free of 1-hexadecyl-2-(3′-carboxy)propyl glycero-3-phosphocholine (impurity A).
1-hexadecyl-2-(4′-carboxy)butyl-sn-glycero-3-phosphocholine (CI-201) being substantially free of an impurity characterized by a HPLC relative retention time of about 0.92 (impurity D).
1-hexadecyl-2-(4′-carboxy)butyl-sn-glycero-3-phosphocholine (CI-201) being substantially free of an impurity characterized by a relative retention time of about 1.05 (impurity C).
Dependencies are inferred from the claim text.